The future for German medtech bright, but not dazzling
This article was originally published in Clinica
Executive Summary
While global banks continue to struggle and the automotive industry has been brought to its knees, the healthcare sector remains relatively buoyant and, dare I say it, primed for the future. In Germany, this can certainly be said of the medical devices industries. Indeed, there have been disappearances from the scene of smaller companies, as well as mergers and acquisition, spurred on by the financial crisis, but there have to date been no grand-scale casualties.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.